TABLE 3.

Risk of cancer associated with levothyroxine stratified by gender

Cancer	Gender	Adjusted odds ratio a (95% CI)	P‐value
Overall	Male	1.32 (1.24‐1.41)	<.0001**
	Female	1.56 (1.51‐1.61)	<.001*
Esophageal	Male	0.60 (0.36‐1.00)	.04
	Female	1.23 (0.69‐2.20)	.48
Gastric	Male	1.49 (1.10‐2.02)	.01
	Female	1.06 (0.85‐1.31)	.61
Colorectal	Male	1.20 (1.02‐1.40)	.02
	Female	1.12 (1.01‐1.23)	.02
Liver	Male	0.87 (0.71‐1.06)	.16
	Female	1.03 (0.89‐1.18)	.70
Pancreatic	Male	1.18 (0.69‐1.99)	.54
	Female	1.30 (1.01‐1.68)	.04
Lung	Male	1.05 (0.88‐1.26)	.58
	Female	1.30 (1.16‐1.45)	<.0001**
Skin	Male	1.53 (1.06‐2.22)	<.001**
	Female	1.39 (1.11‐1.74)	.004
Female Breast	Female	1.24 (1.15‐1.33)	<.0001**
Cervical	Female	0.75 (0.62‐0.91)	.003
Prostate	Male	1.26 (1.06‐1.50)	.01
Bladder	Male	1.04 (0.74‐1.47)	.81
	Female	1.32 (1.06‐1.65)	.012
Kidney	Male	1.13 (0.72‐1.78)	.59
	Female	1.14 (0.90‐1.44)	.26
Brain	Male	2.71 (1.68‐4.37)	<.0001**
	Female	1.64 (1.22‐2.20)	.001**

CI, confidence interval.

^aOdds ratio adjusted for age, gender, comorbid conditions, age‐adjusted Charlson comorbidities index scores, and other drugs in Table 1.

^* P <.01; **P <.001.